Clinical Trial Update: Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Rituximab with Ifosfamide, Carboplatin, and Etoposide for Non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)
• Rituximab (rituximab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Non-Hodgkin's Lymphoma, B-cell Lymphoma | Phase 1 | Status: TERMINATED